PHASE-II STUDY OF VP16-213 (ETOPOSIDE) IN REFRACTORY METASTATIC BREAST-CARCINOMA

被引：0

作者：

SCHELL, FC ^{[1
]}

YAP, HY ^{[1
]}

HORTOBAGYI, GN ^{[1
]}

ISSELL, B ^{[1
]}

ESPARZA, L ^{[1
]}

机构：

[1] BRISTOL MYERS CO LABS,SYRACUSE,NY 13201

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：223 / 225

页数：3

共 15 条

[1] BRODER LE, 1974, CANCER TREAT REV, V1, P183, DOI 10.1016/S0305-7372(74)80002-2
[2] BUZDAR AU, 1978, CANCER, V41, P392, DOI 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO
[3] 2-7
[4] CANNELIOS GP, 1976, ANN INTERN MED, V84, P389
[5] CARDENAS JO, 1975, AM SOC CLIN ONCOL, V16, P231
[6] Carter S K, 1974, Semin Oncol, V1, P131
[7] DELENA M, 1975, CANCER, V35, P1108, DOI 10.1002/1097-0142(197504)35:4<1108::AID-CNCR2820350414>3.0.CO
[8] 2-Z
[9] HORTOBAGYI GN, 1977, RECENT RES CANCER, V62, P143
[10] ETOPOSIDE (VP-16-213)
ISSELL, BF
CROOKE, ST
[J]. CANCER TREATMENT REVIEWS, 1979, 6 (02) : 107 - 124